CA Patent

CA3193811A1 — Compositions and methods of treating amyotrophic lateral sclerosis (als)

Assigned to Voyager Therapeutics Inc · Expires 2016-05-19 · 10y expired

What this patent protects

The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.

USPTO Abstract

The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.

Drugs covered by this patent

Patent Metadata

Patent number
CA3193811A1
Jurisdiction
CA
Classification
—
Expires
2016-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Voyager Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.